November 11, 2014
Article
In this review, we will discuss the current status of several anti–PD-1 and anti–PD-L1 antibodies in clinical development and their direction for the future.
November 10, 2014
Article
Characterizing tumors by PD-L1 expression, immune infiltration, chemokine signature, and tumor mutational frequency may be a means of creating an integrated model for determining which patients may benefit from which immune-checkpoint inhibitors, either alone or in combination.
November 10, 2014
Article
As immune checkpoint–blocking medications are administered to an increasing number of patients, clinicians must be able to recognize and treat the associated immune-related side effects.